Global market valuation was derived through revenue mapping, prescription volume analysis, and procedure administration data. The methodology included:
Identification of 35+ key manufacturers across North America, Europe, Asia-Pacific, and Latin America specializing in allergen immunotherapy extracts, sublingual tablets/drops, and biologic therapeutics
Product mapping across SCIT (aluminum-adsorbed and aqueous extracts), SLIT (tablets and drops), oral immunotherapy protocols, and monoclonal antibody biologics (omalizumab, dupilumab, mepolizumab integration)
Analysis of reported and modeled annual revenues specific to allergy immunotherapy portfolios, including prescription audit data and treatment course completions
Coverage of manufacturers representing 75-80% of global market share in 2024
Extrapolation using bottom-up (treatment volume × ASP by country/region, adjusted for completion rates and drop-offs) and top-down (manufacturer revenue validation, IQVIA prescription validation) approaches to derive segment-specific valuations across allergy indications and patient age demographics
Key differences from your example: Adjusted percentages in primary breakdowns, shifted regional focus slightly toward Europe/Asia-Pacific, included biologics and OIT alongside traditional immunotherapy, and modified manufacturer coverage to reflect the more consolidated nature of the allergen extract market (fewer players than dermal fillers but high market concentration).
